↓ Skip to main content

Dove Medical Press

Article Metrics

Design of multifunctional magnetic iron oxide nanoparticles/mitoxantrone-loaded liposomes for both magnetic resonance imaging and targeted cancer therapy

Overview of attention for article published in International Journal of Nanomedicine, August 2014
Altmetric Badge

About this Attention Score

  • Good Attention Score compared to outputs of the same age (75th percentile)
  • Average Attention Score compared to outputs of the same age and source

Mentioned by

news
1 news outlet

Citations

dimensions_citation
30 Dimensions

Readers on

mendeley
59 Mendeley
Title
Design of multifunctional magnetic iron oxide nanoparticles/mitoxantrone-loaded liposomes for both magnetic resonance imaging and targeted cancer therapy
Published in
International Journal of Nanomedicine, August 2014
DOI 10.2147/ijn.s61880
Pubmed ID
Authors

Yingna He, Linhua Zhang, Cunxian Song, Dunwan Zhu

Abstract

Tumor-targeting multifunctional liposomes simultaneously loaded with magnetic iron oxide nanoparticles (MIONs) as a magnetic resonance imaging (MRI) contrast agent and anticancer drug, mitoxantrone (Mit), were developed for targeted cancer therapy and ultrasensitive MRI. The gonadorelin-functionalized MION/Mit-loaded liposome (Mit-GML) showed significantly increased uptake in luteinizing hormone-releasing hormone (LHRH) receptor overexpressing MCF-7 (Michigan Cancer Foundation-7) breast cancer cells over a gonadorelin-free MION/Mit-loaded liposome (Mit-ML) control, as well as in an LHRH receptor low-expressing Sloan-Kettering HER2 3+ Ovarian Cancer (SK-OV-3) cell control, thereby leading to high cytotoxicity against the MCF-7 human breast tumor cell line. The Mit-GML formulation was more effective and less toxic than equimolar doses of free Mit or Mit-ML in the treatment of LHRH receptors overexpressing MCF-7 breast cancer xenografts in mice. Furthermore, the Mit-GML demonstrated much higher T2 enhancement than did Mit-ML controls in vivo. Collectively, the study indicates that the integrated diagnostic and therapeutic design of Mit-GML nanomedicine potentially allows for the image-guided, target-specific treatment of cancer.

Mendeley readers

The data shown below were compiled from readership statistics for 59 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
India 1 2%
Russia 1 2%
Pakistan 1 2%
Unknown 56 95%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 16 27%
Student > Master 10 17%
Researcher 9 15%
Student > Bachelor 5 8%
Student > Doctoral Student 5 8%
Other 7 12%
Unknown 7 12%
Readers by discipline Count As %
Chemistry 14 24%
Pharmacology, Toxicology and Pharmaceutical Science 12 20%
Medicine and Dentistry 6 10%
Biochemistry, Genetics and Molecular Biology 6 10%
Engineering 5 8%
Other 4 7%
Unknown 12 20%

Attention Score in Context

This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 18 September 2014.
All research outputs
#3,144,531
of 12,438,331 outputs
Outputs from International Journal of Nanomedicine
#266
of 2,456 outputs
Outputs of similar age
#49,773
of 209,442 outputs
Outputs of similar age from International Journal of Nanomedicine
#5
of 21 outputs
Altmetric has tracked 12,438,331 research outputs across all sources so far. This one has received more attention than most of these and is in the 73rd percentile.
So far Altmetric has tracked 2,456 research outputs from this source. They receive a mean Attention Score of 3.0. This one has done well, scoring higher than 88% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 209,442 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 75% of its contemporaries.
We're also able to compare this research output to 21 others from the same source and published within six weeks on either side of this one. This one is in the 42nd percentile – i.e., 42% of its contemporaries scored the same or lower than it.